Bravecto
™
: occurrence of lesions on days before and after treatment (dogs were treated on Day 0: number of dogs/number of dogs per group)
|
---|
Clinical sign
|
Day −4
|
Day 28
|
Day 56
|
Day 84
|
Erythematous patches
|
62.5% (5/8)
|
37.5% (3/8)
|
12.5% (1/8)
|
12.5% (1/8)
|
Crusts, casts or scales
|
100% (8/8)
|
62.5% (5/8)
|
62.5% (5/8)
|
12.5% (1/8)
|
Advocate®; occurrence of lesions on days before and after initial treatment (dogs were treated on Days 0, 28 and 56
a
: number of dogs/number of dogs per group)
|
Clinical sign
|
Day −4
|
Day 28
|
Day 56
|
Day 84
|
Erythematous patches
|
87.5% (7/8)
|
50% (4/8)
|
0% (0/8)
|
0% (0/7)b
|
Crusts, casts or scales
|
100% (8/8)
|
100% (8/8)
|
37.5% (3/8)
|
42.9% (3/7)b
|
-
aSkin assessments were performed before treatment.
-
bOn day 59 one dog had to be euthanized due to the presence of a malign tumour in the stomach.